ADME of Antibody–Maytansinoid Conjugates

Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 4

Abstract

The concept of treating cancer with antibody-drug conjugates (ADCs) has gained momentum with the favorable activity and safety of trastuzumab emtansine (T-DM1), SAR3419, and lorvotuzumab mertansine (IMGN901). All three ADCs utilize maytansinoid cell-killing agents which target tubulin and suppress microtubule dynamics. Each ADC utilizes a different optimized chemical linker to attach the maytansinoid to the antibody. Characterizing the absorption, distribution, metabolism, and excretion (ADME) of these ADCs in preclinical animal models is important to understanding their efficacy and safety profiles. The ADME properties of these ADCs in rodents were inferred from studies with radio-labeled ADCs prepared with nonbinding antibodies since T-DM1, SAR3419, IMGN901 all lack cross-reactivity with rodent antigens. For studies exploring tumor localization and activation in tumor-bearing mice, tritium-labeled T-DM1, SAR3419, and IMGN901 were utilized. The chemical nature of the linker was found to have a significant impact on the ADME properties of these ADCs—particularly on the plasma pharmacokinetics and observed catabolites in tumor and liver tissues. Despite these differences, T-DM1, SAR3419, and IMGN901 were all found to facilitate efficient deliveries of active maytansinoid catabolites to the tumor tissue in mouse xenograft models. In addition, all three ADCs were effectively detoxified during hepatobiliary elimination in rodents.

Authors and Affiliations

Hans K. Erickson, John M. Lambert

Keywords

Related Articles

A History of Biopharmaceutics in the Food and Drug Administration 1968–1993

The history of biopharmaceutics is reviewed, beginning with its origin out of the Division of Clinical Research in The Bureau of Medicine. The reason for the creation of the Division of Biopharmaceutics, the certificatio...

Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques

The purpose of this study was to identify optimal preservatives for a multidose formulation of a humanized monoclonal antibody using experimental design techniques. The effect of antimicrobial parenteral preservatives (b...

Pocket-Based Drug Design: Exploring Pocket Space

The online version of this article (doi:10.1208/s12248-012-9426-6) contains supplementary material, which is available to authorized users.

Investigation of the Performance of the Disintegration Test for Dietary Supplements

The aim of this study was to investigate how beaker size, basket assembly, use of disk, and immersion medium impact the disintegration time of dietary supplements. The disintegration times were determined for five tablet...

R4 Regulator of G Protein Signaling (RGS) Proteins in Inflammation and Immunity

G protein-coupled receptors (GPCRs) have important functions in both innate and adaptive immunity, with the capacity to bridge interactions between the two arms of the host responses to pathogens through direct recogniti...

Download PDF file
  • EP ID EP681276
  • DOI  10.1208/s12248-012-9386-x
  • Views 64
  • Downloads 0

How To Cite

Hans K. Erickson, John M. Lambert (2012). ADME of Antibody–Maytansinoid Conjugates. The AAPS Journal, 14(4), -. https://europub.co.uk/articles/-A-681276